PMID- 19275691
OWN - NLM
STAT- MEDLINE
DCOM- 20091110
LR  - 20211203
IS  - 2212-4055 (Electronic)
IS  - 1871-5281 (Linking)
VI  - 8
IP  - 1
DP  - 2009 Mar
TI  - Molecular basis of the anti-inflammatory effects of terpenoids.
PG  - 28-39
AB  - Natural products play a significant role in human health in relation to the 
      prevention and treatment of inflammatory conditions. Among them, terpenoids (also 
      referred to as terpenes), are the largest and most widespread class of secondary 
      metabolites. They are found in higher plants, mosses, liverworts, algae and 
      lichens, and also in insects, microbes or marine organisms. Some terpenoids have 
      been used for therapeutic purposes for centuries as antibacterial, 
      anti-inflammatory, antitumoral agents, and in recent decades research activity 
      into the clinical potential of this class of compounds has increased continuously 
      as a source of pharmacologically interesting agents. In the present review, 
      molecular basis of the anti-inflammatory action of diterpenoids is presented with 
      special emphasis on their ability to modulate critical cell signaling pathways 
      involved in the inflammatory response of the body such as nuclear transcription 
      factor-kappaB (NF-kappaB) activation. NF-kappaB plays an important role in the 
      regulation of immune and inflammatory responses. Indeed, deregulated NF-kappaB 
      expression is a characteristic phenomenon in several inflammatory diseases and 
      NF-kappaB has become a major target in drug discovery. Hence, this article also 
      introduces our recently elucidated findings about the potential of labdane 
      diterpenoids as anti-inflammatory agents due to their ability to inhibit 
      NF-kappaB. The future development of this class of compounds as anti-inflammatory 
      drugs requires the introduction of novel molecular targets of therapeutic 
      relevance in addition to biotechnological approaches for the production of these 
      molecules.
FAU - de las Heras, B
AU  - de las Heras B
AD  - Departamento de Farmacologia, Facultad de Farmacia, Universidad Complutense, 
      Madrid, Spain.
FAU - Hortelano, Sonsoles
AU  - Hortelano S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Inflamm Allergy Drug Targets
JT  - Inflammation & allergy drug targets
JID - 101266886
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Diterpenes)
RN  - 0 (NF-kappa B)
RN  - 0 (Terpenes)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/classification/therapeutic use
MH  - Autoimmune Diseases/drug therapy
MH  - Diterpenes/*pharmacology
MH  - Drug Therapy/trends
MH  - Humans
MH  - Hypersensitivity/drug therapy
MH  - Immunosuppression Therapy
MH  - *Medicine, Traditional
MH  - NF-kappa B/*antagonists & inhibitors
MH  - Neoplasms/drug therapy
MH  - Signal Transduction/*drug effects/immunology
MH  - Terpenes/classification/therapeutic use
MH  - Transcriptional Activation/*drug effects/immunology
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
RF  - 83
EDAT- 2009/03/12 09:00
MHDA- 2009/11/11 06:00
CRDT- 2009/03/12 09:00
PHST- 2009/03/12 09:00 [entrez]
PHST- 2009/03/12 09:00 [pubmed]
PHST- 2009/11/11 06:00 [medline]
AID - 10.2174/187152809787582534 [doi]
PST - ppublish
SO  - Inflamm Allergy Drug Targets. 2009 Mar;8(1):28-39. doi: 
      10.2174/187152809787582534.